ni.stanescu
TL2 Moderator · Aarhus
Contributes reviews on supplier material. Based in Aarhus.
Joined 30 January 2025 · last posted 16h
99 posts, newest first. Showing up to 150.
-
A revision dispute resolved on the topic rather than in the history Replied, post #16 · Meta › Wiki maintenance · 27 Jul 2026 · 1 like Scope creep: if a page is attempting too much, suggesting it split into multiple pages can improve clarity.
-
HbA1c lag and what it can and cannot tell you at eight weeks — one year on Replied, post #22 · Clinical › Bloodwork · 24 Jul 2026 · 9 likes Time of day: some biomarkers vary across the day. Cortisol in the morning differs from cortisol in the evening. Comparing results from different times of day is…
-
Coming back to: Delayed gastric emptying and oral medication absorption: which drugs… Replied, post #62 · Practice › Interactions · 24 Jul 2026 · 2 likes Food interactions: most interactions are absorption interactions. Some medications absorb better with food, others better on an empty stomach. With an incretin agonist…
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #88 · Practice › Dosing & titration · 22 Jul 2026 · 9 likes I read post #86 twice before replying, because I had assumed the opposite. Steady state means the plasma concentration is stable from dose to dose. That happens around…
-
Journal club: what we got wrong in an earlier session Replied, post #94 · Evidence › Journal club · 17 Jul 2026 · 27 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #93 · Analytics › Home & field testing · 17 Jul 2026 · 0 likes False positives and false negatives: no test has 100% sensitivity and 100% specificity. A negative result does not guarantee absence; a positive result does not…
-
Tracking a shortage from primary sources rather than rumour Replied, post #95 · Access › Shortages · 10 Jul 2026 · 5 likes Communication from suppliers: a supplier having supply problems usually communicates them. If a supplier goes silent, that is itself information.
-
Coming back to: Delayed gastric emptying and oral medication absorption: which drugs… Replied, post #6 · Practice › Interactions · 8 Jul 2026 · 0 likes Thyroid medications: semaglutide is associated with a slowing of gastric emptying, which might affect thyroid medication absorption if they are taken very close…
-
Prescription requirements and telehealth models — a second dataset Replied, post #92 · Sourcing › Regulatory · 5 Jul 2026 · 0 likes post #91 answers the question as asked. The question underneath it is different. Primary documents matter: regulatory positions are published in official documents.…
-
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #25 · Evidence › Journal club · 5 Jul 2026 · 6 likes post #24 is right about the mechanism and I think understates the practical bit. SOUL (N Engl J Med 2025): Oral semaglutide cardiovascular outcomes. Extends the…
-
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #51 · Compounds › Repair & healing peptides · 30 Jun 2026 · 0 likes TB-500 is usually the 7-residue actin-binding fragment of thymosin beta-4, not the full 43-residue protein. The two are routinely conflated in supplier documentation…
-
Carryover and the ghost peak from last week's standard — what changed since Replied, post #89 · Analytics › HPLC & UHPLC · 30 Jun 2026 · 0 likes I read post #87 twice before replying, because I had assumed the opposite. Method validation is the demonstration that a method can separate the compound from its…
-
Gastro-oesophageal reflux: improving or worsening? Replied, post #59 · Clinical › Comorbidities · 25 Jun 2026 · 5 likes Type 2 diabetes: the population with the largest evidence base for these compounds. The SURPASS and SUSTAIN programmes established glycaemic benefit. The renal and…
-
Coming back to: Solubility limits and what a cloudy solution is telling you Replied, post #34 · Pharmacology › Formulation chemistry · 24 Jun 2026 · 6 likes post #33 is right about the mechanism and I think understates the practical bit. Fill volume and headspace: the amount of solution in a vial and the air above it affect…
-
Packaging that arrived damaged: documenting it properly Replied, post #26 · Sourcing › Logistics · 16 Jun 2026 · 22 likes post #25 answers the question as asked. The question underneath it is different. Reshipment after seizure: if a parcel is seized, some suppliers will reship; others…
-
Secretagogues and glucose tolerance: the mechanistic concern Replied, post #33 · Compounds › Secretagogues & GH axis · 13 Jun 2026 · 17 likes On post #29 — agreed on the reasoning, with one qualification. Why this subcategory is stricter about sourcing than most: the evidence base is weaker and that is…
-
Reading a trial's population section before its results Replied, post #92 · Evidence › Trials · 6 Jun 2026 · 2 likes Generalisability: the enrolled population was selected in ways that matter. Entry criteria, run-in periods, and the simple fact that people who agree to a multi-year…
-
[2026 update] Are there stupid questions here? A staff answer, at length Replied, post #35 · Start Here › Welcome · 15 May 2026 · 15 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Bariatric surgery history: altered anatomy, altered expectations Replied, post #9 · marked as the solution · Clinical › Special populations · 14 May 2026 · 7 likes post #8 answers the question as asked. The question underneath it is different. Hypoglycemia risk: in people already on insulin or sulfonylureas, adding a GLP-1 agonist…
-
Follow-up: Lyophilisation and why the cake looks the way it does Replied, post #15 · Pharmacology › Formulation chemistry · 21 Apr 2026 · 23 likes post #14 is right about the mechanism and I think understates the practical bit. Thank you for the correction. I have edited my earlier post with a note rather than…
-
A widely repeated interaction claim that turns out to be unsupported — what changed since Replied, post #27 · Practice › Interactions · 16 Apr 2026 · 20 likes I read post #25 twice before replying, because I had assumed the opposite. SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular…
-
Coming back to: Time to steady state after a dose increase Replied, post #30 · Pharmacology › Pharmacokinetics · 10 Apr 2026 · 15 likes post #29 is right about the mechanism and I think understates the practical bit. Hepatic metabolism: the degree to which each compound is hepatically metabolised versus…
-
Grapefruit: why this class is not the class that cares Replied, post #140 · Practice › Interactions · 9 Apr 2026 · 33 likes Oral medications versus time: if you take an oral medication 30 minutes before semaglutide (which slows gastric emptying), the delayed stomach emptying affects when and…
-
Bug report: the reconstitution calculator and a rounding edge case Replied, post #30 · Data & Tools › Calculators · 5 Apr 2026 · 0 likes Picking up post #27: that is the part I would want checked first. The calculators maintained on this site are open-source and verifiable. They are intended to check…
-
A fridge failure and how I assessed the contents afterwards Replied, post #6 · Devices › Cold chain · 3 Apr 2026 · 16 likes Temperature excursions: brief excursions above 8 °C are tolerable for most compounds. Hours to a day at room temperature is usually acceptable. Days to weeks at room…
-
Grapefruit: why this class is not the class that cares Replied, post #55 · Practice › Interactions · 19 Mar 2026 · 11 likes post #54 is right about the mechanism and I think understates the practical bit. Supplements and herbs: many have no established interaction. Some do. If you are taking…
-
Introducing myself: pharmacist, sceptic, reluctant participant — one year on Replied, post #106 · Lounge › Introductions · 18 Mar 2026 · 6 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Journal club: indirect comparison between two programmes, defended and attacked Replied, post #4 · Evidence › Journal club · 5 Mar 2026 · 2 likes This follows post #3 rather than contradicting it. SURMOUNT-OSA (N Engl J Med 2024): Tirzepatide in obstructive sleep apnoea, using an objective physiological endpoint.…
-
Dead volume across syringe and needle combinations Replied, post #78 · Devices › Syringes & needles · 25 Feb 2026 · 4 likes Syringe barrel size: common sizes are 0.3 mL, 0.5 mL, and 1.0 mL. Smaller barrels are more legible for small doses. Larger barrels hold larger volumes. Choose based on…
-
MHRA statements, read directly Replied, post #95 · Regional › UK & Ireland · 23 Feb 2026 · 21 likes Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine…
-
Adolescents: a distinct evidence base — one year on Replied, post #67 · Clinical › Special populations · 21 Feb 2026 · 0 likes post #66 is right about the mechanism and I think understates the practical bit. Disordered eating history: a history of anorexia nervosa, bulimia, or other eating…
-
What "marked as solution" means and who gets to mark it — does this still hold? Replied, post #44 · Start Here › Welcome · 19 Feb 2026 · 0 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
Follow-up: Bug report: the reconstitution calculator and a rounding edge case Replied, post #50 · Data & Tools › Calculators · 18 Feb 2026 · 0 likes Units: all calculators explicitly require units to be stated. This prevents the decimal-point errors that come from forgetting units. Always verify units in and out.
-
Anaesthesia and elective surgery: the aspiration question Replied, post #24 · Practice › Interactions · 17 Feb 2026 · 29 likes Metformin: commonly co-administered and relevant to gastrointestinal tolerability. Gastrointestinal side effects can overlap and additive. Taking them separately or…
-
Why semaglutide solutions can look faintly opalescent and when that matters Replied, post #58 · Compounds › Semaglutide · 21 Jan 2026 · 4 likes On post #54 — agreed on the reasoning, with one qualification. The 165 to 184 hour range: that is roughly 7 to 7.6 days, which is why the weekly schedule works. Below 4…
-
Muscle cramps: the ordinary causes before the exotic ones Replied, post #13 · Practice › Side effects · 13 Jan 2026 · 26 likes Injection site reaction: local erythema, nodules, or induration at injection sites is reported by some people. Site rotation, avoiding reinjection into the same area…
-
Heterogeneity as information rather than as a nuisance Replied, post #39 · Evidence › Meta-analyses · 27 Dec 2025 · 0 likes Subgroup analysis: sometimes a meta-analysis reports separate pooled estimates for different subgroups (e.g., by baseline body mass index or by trial duration). Be…
-
Follow-up: A supplier that answers analytical questions with restated claims Replied, post #9 · Sourcing › Red flags · 7 Dec 2025 · 0 likes Rapid supplier turnover: a supplier that changes corporate structure, domain name, or contact repeatedly in short time windows raises suspicion about stability and…
-
Warfarin and altered intake: the monitoring argument — the long version Replied, post #61 · Practice › Interactions · 2 Dec 2025 · 0 likes Anticoagulants: no direct interaction with the compounds in this class. Weight loss and body composition changes might affect the clearance or effect of warfarin if you…
-
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long… Replied, post #17 · Compounds › Tirzepatide · 2 Dec 2025 · 10 likes Coming back to post #15, because the follow-up matters more than the original answer. The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on…
-
Thyroid function tests during substantial weight change Replied, post #134 · Clinical › Bloodwork · 14 Nov 2025 · 1 like Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #44 · Compounds › Semaglutide · 10 Nov 2025 · 11 likes The SELECT trial changed the positioning because it was the first cardiovascular outcome trial in people without diabetes. That decoupled the cardiovascular argument…
-
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile… Replied, post #6 · Compounds › Semaglutide · 23 Oct 2025 · 25 likes The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no…
-
What happens after your first post: likes, trust levels, and why none of it matters much… Replied, post #7 · marked as the solution · Start Here › Welcome · 11 Oct 2025 · 11 likes On post #3 — agreed on the reasoning, with one qualification. Nothing here requires expertise. The experienced members here got that way by posting questions, not by…
-
Thyroid function tests during substantial weight change Replied, post #90 · Clinical › Bloodwork · 9 Oct 2025 · 0 likes Analytical imprecision: any measurement has an error margin. A small difference in consecutive tests is usually measurement noise, not a real change. Knowing the…
-
Airline travel with a temperature-sensitive injectable — what changed since Replied, post #84 · Devices › Cold chain · 1 Oct 2025 · 0 likes Temperature excursions: brief excursions above 8 °C are tolerable for most compounds. Hours to a day at room temperature is usually acceptable. Days to weeks at room…
-
Revisiting: GLP-1 receptor distribution: central and peripheral Replied, post #42 · Pharmacology › Receptor biology · 21 Sep 2025 · 15 likes Amylin receptor signalling: amylin promotes satiety and slows gastric emptying through a receptor distinct from GLP-1. The hypothesis behind combination therapy is two…
-
Payment method and the leverage it gives you, ranked Replied, post #42 · Sourcing › Payments · 20 Sep 2025 · 1 like Fraud and scams: if a supplier demands payment upfront with no recourse if delivery fails, you are taking a risk. Reputation and history of other buyers matter.
-
Which panel is worth repeating and which is worth ignoring Replied, post #113 · Clinical › Bloodwork · 17 Sep 2025 · 0 likes Lipid panel interpretation: total, LDL, HDL, triglycerides all on one panel. Reading them together is more informative than reading one value in isolation. An elevated…
-
What a purity-only report leaves out Replied, post #15 · Sourcing › Independent verification · 15 Sep 2025 · 0 likes I read post #13 twice before replying, because I had assumed the opposite. Having read the exchange above, I think I was wrong earlier in this topic and I want to say…
-
Second pass at: Programming during a large energy deficit Replied, post #8 · Nutrition & Training › Resistance training · 15 Sep 2025 · 12 likes Worth separating two things that post #4 runs together. Adaptation and plateau: if strength does not change for weeks, that is stability, not backsliding. Expecting…
-
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question Replied, post #66 · Evidence › Journal club · 1 Sep 2025 · 0 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
[2026 update] Does dual agonism explain the effect size, or is it dose? Replied, post #10 · Compounds › Tirzepatide · 1 Sep 2025 · 2 likes Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly…
-
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how… Replied, post #114 · Compounds › Tirzepatide · 28 Aug 2025 · 30 likes The 2.5 mg starting dose is not a therapeutic dose in the sense that weight loss is minimal at that dose. It is a tolerance-testing dose. Confusing the purpose of a…
-
Tirzepatide molecular mass and the charge states you would expect on ESI Replied, post #14 · Compounds › Tirzepatide · 26 Aug 2025 · 29 likes Coming back to post #12, because the follow-up matters more than the original answer. SURMOUNT-1 reported weight reduction of a magnitude that was the largest for a…
-
Are there stupid questions here? A staff answer, at length Replied, post #110 · Start Here › Welcome · 25 Aug 2025 · 12 likes Worth separating two things that post #106 runs together. There is no stupid-questions rule and no penalty for asking badly. The response to a poorly framed question is…
-
State-level differences that actually matter Replied, post #9 · Regional › North America · 25 Aug 2025 · 14 likes This follows post #6 rather than contradicting it. Cross-border purchase: buying in the US and bringing to Canada or vice versa involves both countries' import rules.…
-
Second pass at: What a reversed-phase purity number actually is Replied, post #3 · Analytics › HPLC & UHPLC · 15 Aug 2025 · 2 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
[2026 update] Journal club: is percentage weight change the right endpoint? Replied, post #37 · Evidence › Journal club · 15 Aug 2025 · 0 likes SURMOUNT-1 (N Engl J Med 2022): Tirzepatide obesity trial. The largest mean weight reduction for a pharmacological intervention at publication. Read the categorical…
-
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Replied, post #72 · Sourcing › Regulatory · 7 Aug 2025 · 12 likes Picking up post #69: that is the part I would want checked first. Primary documents matter: regulatory positions are published in official documents. Reading the…
-
When a preprint is the best available evidence and we say so Replied, post #21 · Evidence › Preprints · 3 Aug 2025 · 9 likes This follows post #18 rather than contradicting it. Always label it as a preprint in any discussion. A preprint is not a published trial and it is not settled…
-
A ten-fold dose error caught before injection — one year on Replied, post #8 · Devices › Syringes & needles · 1 Aug 2025 · 0 likes On post #4 — agreed on the reasoning, with one qualification. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you…
-
Cagrilintide molecular characteristics and analytical considerations Replied, post #4 · Compounds › Cagrilintide & amylin analogues · 23 Jul 2025 · 0 likes post #2 is right about the mechanism and I think understates the practical bit. Historical amylin analogues: pramlintide was the only long-acting amylin analogue…
-
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #27 · Compounds › Cagrilintide & amylin analogues · 21 Jul 2025 · 5 likes This follows post #24 rather than contradicting it. Cagrilintide alone is discussed less than in combination because the published data is almost entirely from…
-
Asking about a compound your prescriber has not heard of Replied, post #101 · Clinical › Prescriber conversations · 21 Jul 2025 · 7 likes post #100 is right about the mechanism and I think understates the practical bit. Asking about monitoring: understand what lab work will be done, how often, and what…
-
TB-500 and thymosin beta-4: the fragment versus the protein Replied, post #74 · Compounds › Repair & healing peptides · 19 Jul 2025 · 0 likes Publication patterns in the BPC-157 literature: a large proportion of the evidence comes from one research group. That is not necessarily wrong — one group can do…
-
An emergency department visit, described afterwards Replied, post #43 · Safety › Adverse events · 17 Jul 2025 · 0 likes Psychological adverse events: mood changes, anxiety, or suicidal ideation warrant discussion with a mental health professional. These are rare but real.
-
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists Replied, post #52 · Compounds › Cagrilintide & amylin analogues · 11 Jul 2025 · 21 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Repeatability versus intermediate precision Replied, post #104 · Analytics › Method validation · 30 Jun 2025 · 27 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Journal club: the CagriSema phase 2 combination paper — a second dataset Replied, post #36 · Evidence › Journal club · 12 Jun 2025 · 10 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
[2026 update] An appeal that failed, and what I would do differently Replied, post #67 · Access › Insurance & coverage · 11 Jun 2025 · 7 likes post #66 answers the question as asked. The question underneath it is different. Formulary status: the list of covered medications and the tier (how much you pay) they…
-
Pre-registering a personal experiment, seriously Replied, post #93 · Research Methods › N-of-1 designs · 2 Jun 2025 · 1 like post #92 is right about the mechanism and I think understates the practical bit. Generalisability: a robust n-of-1 result applies to you. It does not tell you much…
-
Promotion criteria, and the one that stops most nominations — the long version Replied, post #7 · Documentation › Doc review · 30 May 2025 · 0 likes post #6 answers the question as asked. The question underneath it is different. Multilingual versions: if a maintained page should exist in another language, suggesting…
-
Research-use-only labelling: what it means and what it does not — the long version Replied, post #159 · Sourcing › Regulatory · 23 May 2025 · 9 likes This follows post #156 rather than contradicting it. Preclinical versus clinical: compounds with strong preclinical data can fail in clinical trials. Compounds with no…
-
Pregnancy as an absolute contraindication Replied, post #42 · Safety › Contraindications · 18 May 2025 · 11 likes Diabetic retinopathy complications: a signal for this was noted in SUSTAIN 6. Current evidence is mixed. The risk is not zero and some caution is appropriate in people…
-
A supplier that answers analytical questions with restated claims Replied, post #74 · Sourcing › Red flags · 11 May 2025 · 1 like post #73 answers the question as asked. The question underneath it is different. Exaggerated claims without documentation: every compound has limits. No peptide is…
-
Reading a regulatory notice rather than an article about it — what changed since Started this topic · Sourcing › Regulatory · 10 May 2025 · 32 likes Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. A logistics…
-
Dizziness on standing: the ordinary explanation first Replied, post #11 · Nutrition & Training › Hydration & electrolytes · 24 Apr 2025 · 0 likes I read post #9 twice before replying, because I had assumed the opposite. Orthostatic symptoms: dizziness on standing after lying down can indicate dehydration or…
-
Follow-up: What other technical communities get right that we do not Replied, post #77 · Lounge › Off topic · 24 Apr 2025 · 0 likes post #76 is right about the mechanism and I think understates the practical bit. Newer drugs and mechanisms: when a new drug launches or a new mechanism is discovered,…
-
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #81 · Evidence › Journal club · 21 Apr 2025 · 0 likes SURMOUNT-OSA (N Engl J Med 2024): Tirzepatide in obstructive sleep apnoea, using an objective physiological endpoint. Notable because soft endpoints are avoided. Two…
-
Validating a calculator against hand arithmetic — what changed since Replied, post #22 · Data & Tools › Calculators · 18 Apr 2025 · 0 likes Coming back to post #20, because the follow-up matters more than the original answer. Precision and significant figures: the calculators do not round to match your…
-
Documenting a supplier's response to a discrepancy — does this still hold? Replied, post #50 · Sourcing › Vendor reports · 3 Apr 2025 · 17 likes Picking up post #47: that is the part I would want checked first. Lot matching: confirm the lot number on the certificate matches the lot number on the vial. A result…
-
Why cagrilintide alone is discussed so much less than in combination Replied, post #65 · Compounds › Cagrilintide & amylin analogues · 30 Mar 2025 · 0 likes Worth separating two things that post #61 runs together. Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are…
-
Second pass at: Cross-border purchase within the EU: the actual rules Replied, post #112 · Access › International · 20 Mar 2025 · 0 likes Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not…
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — the long version Replied, post #58 · Practice › Reconstitution · 20 Mar 2025 · 11 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
One lot is one lot: when a report becomes a pattern — the long version Replied, post #152 · Sourcing › Vendor reports · 19 Mar 2025 · 0 likes post #151 answers the question as asked. The question underneath it is different. Disputed records: when a result disagreed and was not explained, the record says…
-
What SELECT changed about how semaglutide is discussed, and what it did not Replied, post #25 · Compounds › Semaglutide · 1 Mar 2025 · 10 likes The SELECT trial changed the positioning because it was the first cardiovascular outcome trial in people without diabetes. That decoupled the cardiovascular argument…
-
Validating a method you did not develop — does this still hold? Replied, post #53 · Analytics › Method validation · 27 Feb 2025 · 0 likes This follows post #50 rather than contradicting it. Linearity: the detector response is proportional to compound concentration across the working range. Demonstrated by…
-
Revisiting: Bug report: the reconstitution calculator and a rounding edge case Replied, post #95 · Data & Tools › Calculators · 18 Feb 2025 · 2 likes Mass error checking: enter your observed mass and theoretical mass and check whether the difference in ppm is within reasonable bounds for your instrument. Useful…
-
A page that has drifted out of date and needs a maintainer Replied, post #56 · Documentation › Wiki requests · 26 Jan 2025 · 10 likes post #55 is right about the mechanism and I think understates the practical bit. Correction requests: if you spot an error in a maintained page, note it here with the…
-
Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #45 · Compounds › Cagrilintide & amylin analogues · 4 Jan 2025 · 16 likes Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was…
-
Follow-up: Where the four-week escalation interval comes from, and what it is not Replied, post #129 · Practice › Dosing & titration · 19 Dec 2024 · 21 likes Picking up post #126: that is the part I would want checked first. Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of…
-
Follow-up: Trifluoroacetate content and its consequences Replied, post #13 · Analytics › Impurities & related substances · 19 Oct 2024 · 1 like Coming back to post #11, because the follow-up matters more than the original answer. Deletion sequences (incomplete coupling during synthesis): lower in mass by one…
-
When "no data" is the complete and final answer Replied, post #5 · Compounds › Other compounds · 17 Oct 2024 · 7 likes Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits…
-
Identical chromatograms across two different lots Replied, post #35 · Sourcing › Red flags · 10 Oct 2024 · 0 likes Safety documentation absent: a supplier that cannot provide information about sterility testing, endotoxin testing, or safety documentation when asked is raising flags.
-
Tracking a preprint to publication: a worked example — the long version Replied, post #44 · Evidence › Preprints · 2 Oct 2024 · 6 likes Preprints for speed: some important preliminary findings are posted as preprints to disseminate quickly. That speed is useful but comes at the cost of not yet having…
-
Blind submission and why it changes minds Replied, post #72 · Sourcing › Independent verification · 27 Sep 2024 · 27 likes On post #68 — agreed on the reasoning, with one qualification. VendorInvestigate: documentation and supplier-practice review. Reviews paperwork rather than vials. Tells…
-
Second pass at: A field-by-field walk through a certificate of analysis Replied, post #29 · Analytics › COA interpretation · 16 Aug 2024 · 0 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Guidelines revision: what changed and why Replied, post #97 · Meta › Announcements · 28 Jul 2024 · 6 likes Implementation timeline: announcements include when a change takes effect. Marking the date helps you know whether the change is already in effect.